Invention Grant
- Patent Title: Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
-
Application No.: US16310285Application Date: 2017-06-08
-
Publication No.: US11001636B2Publication Date: 2021-05-11
- Inventor: Hans-Georg Lerchen , Anne-Sophie Rebstock , Yolanda Cancho Grande , Sven Wittrock , Beatrix Stelte-Ludwig , Dennis Kirchhoff , Christoph Mahlert , Simone Greven , Stephan Märsch
- Applicant: Bayer Pharma Aktiengesellschaft
- Applicant Address: DE Berlin
- Assignee: Bayer Pharma Aktiengesellschaft
- Current Assignee: Bayer Pharma Aktiengesellschaft
- Current Assignee Address: DE Berlin
- Agency: Wilson Sonsini Goodrich & Rosati
- Priority: EP16174654 20160615
- International Application: PCT/EP2017/063951 WO 20170608
- International Announcement: WO2017/216028 WO 20171221
- Main IPC: A61K39/00
- IPC: A61K39/00 ; C07K16/28 ; A61K47/68 ; A61P35/00 ; A61K31/40
Abstract:
The invention relates to specific Antibody-Drug-Conjugates (ADCs) with KSP inhibitors and anti-CD 123-antibodies, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.
Public/Granted literature
- US20190330357A1 SPECIFIC ANTIBODY-DRUG-CONJUGATES (ADCS) WITH KSP INHIBITORS AND ANTI-CD123-ANTIBODIES Public/Granted day:2019-10-31
Information query
